Search

Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway

Heart Diseases

Diabetes

Heart Failure

NVSS: The Future Vets & Scientists | Boehringer Ingelheim US

Click here to read more on the annual National Veterinary Scholars Symposium, celebrating future veterinarians and scientists across the USA.

Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment

Boehringer Ingelheim and Vanderbilt University join forces

Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists

Immunology

Welcome to the Neuroscience Gallery | Boehringer Ingelheim US

Click here to take a guided tour through our Neuroscience virtual 3-D art exhibition, helping us to improve how we diagnose and treat various diseases.

New consortium EUbOPEN will provide tools to unlock disease biolog

Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders

Oncology & Cancer Immunology

Partnering Days

Oncology & Cancer Immunology

Advocating for More Patient-Centered Mental Health Care

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance

Retinal Health

Prioritizing mental health and well-being today and every day

Prioritizing Mental Health and Well-being Today and Everyday

Championing Novel Science

CIA Reporting Requirements

Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

Why cancer care is personal for us

At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway

Heart Diseases

Diabetes

Heart Failure

NVSS: The Future Vets & Scientists | Boehringer Ingelheim US

Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment

Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists

Immunology

Welcome to the Neuroscience Gallery | Boehringer Ingelheim US

New consortium EUbOPEN will provide tools to unlock disease biolog

Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders

Oncology & Cancer Immunology

Partnering Days

Oncology & Cancer Immunology

Advocating for More Patient-Centered Mental Health Care

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance

Retinal Health

Prioritizing mental health and well-being today and every day

Championing Novel Science

CIA Reporting Requirements

Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

Why cancer care is personal for us